PEA for Flu, Colds, COVID & Long COVID: The Supplement That Worked Too Well? | LYLL #260

Summary

Dr. Garrett Smith explores the history, research, and application of Palmitoylethanolamide (PEA) as an effective, endogenous anti-inflammatory agent for respiratory infections, chronic pain, and long-COVID symptoms.

Highlights

Part 1: Introduction to PEA00:00:00

Dr. Garrett Smith introduces Palmitoylethanolamide (PEA), highlighting that while research shows it can prevent colds and the flu, its history is complicated by suppression and the promotion of 'patented' micronized versions.

Part 2: The Efficacy and Suppression of PEA00:03:35

Discussion of historical research, including Spanish government reimbursement program, showing PEA's long-standing efficacy as a preventative measure for respiratory infections in thousands of patients.

Part 3: Avoiding Micronized and Ultramicronized Forms00:06:20

Dr. Smith explains why he recommends against micronized or ultramicronized PEA, citing potential contamination with additives like polyvinyl pyrrolidone (PVP) and the unnecessary heat processing of these lipid-based compounds.

Part 4: PEA for Long-COVID and Neuroinflammation01:01:07

Exploration of PEA's role in addressing long-COVID symptoms, neuroinflammation, and how it modulates mass cell activation, which the doctor links to his 'toxic bile paradigm'.

Part 5: Dosage and Practical Use01:15:48

Guidance on appropriate dosing, differentiating between PEA and Phenyl ethylamine (PEA), and personal anecdotes regarding the use of PEA as a tool for health despite mainstream opposition.